The trust that runs the major hospitals in Shropshire is taking part in a new lung cancer study to find alternative ...

The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.

Incredible advancements in lung cancer treatment are allowing doctors to target cancer with more precise drugs.

Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid ...

Suchan still needed chemotherapy and radiation, but Salgia credits Rybrevant for shrinking her tumors 60 to 70%. It specifically targets her cancer cells and revs up the immune system. For a year and ...

As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...

Abenacianine, a fluorescent imaging agent, received FDA fast track status for enhancing tumor visualization during lung cancer surgery, showing safety and efficacy in phase 2 trials. Alecensa ...

A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this ...

A targeted therapy called sevabertinib has been approved for patients with non-small cell lung cancer that carries an activating mutation in the HER2 gene.

Cancer survival might depend on what time of day you get your treatment, a new study says. Lung cancer patients who received IV immunotherapy doses earlier in the day tended to live longer, ...

Immunotherapy is a cancer treatment that harnesses the body’s immune system to fight cancer. It helps the immune system recognize and attack cancer cells, which can sometimes be hidden from the body’s ...